HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process-Reference-Cited by-同舟云学术

HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process

Published:2002-04-15 Issue:8 Volume:94 Page:2169-2173
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Vincent-Salomon Anne,Jouve Michel,Genin Pascal,Fréneaux Paul,Sigal-Zafrani Brigitte,Caly Martial,Beuzeboc Philippe,Pouillart Pierre,Sastre-Garau Xavier

Funder

Produits Roche, Neuilly-sur-Seine, France

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference20 articles.

1. Use of chemotherapy plus monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2;Slamon;New Engl J Med.,2001

2. Prognostic importance of c-erbB-2 expression in breast cancer;Gusterson;J Clin Oncol.,1992

3. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma;Allred;J Clin Oncol.,1992

4. Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of ERBB2 (HER-2/neu) gene status in breast carcinoma;Couturier;Mod Pathol.,2000

5. Inflammatory breast carcinoma: an immunohistochemical study using monoclonal anti-pHER-2/neu, pS2, cathepsin, ER and PR;Charpin;Anticancer Res.,1992

Cited by 102 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Receptor Discordance in Metastatic Breast Cancer; a review of clinical and genetic subtype alterations from primary to metastatic disease;Breast Cancer Research and Treatment;2024-08-01

2. Alteration in Steroid Hormone and HER2/neu Receptor Status Following Neoadjuvant Chemotherapy in Triple Negative Breast Cancer. Is There Any Hope?;JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH;2021

3. The Potential Usefulness of 99mTc-HYNIC-(Ser)3-LTVPWY Peptide for Predicting HER2 Status Alteration After Chemotherapy in Ovarian Tumor-Bearing Mice;Cancer Biotherapy and Radiopharmaceuticals;2020-09-07

4. New Insights to Reshape the Management of Patients with Metastatic Breast Cancer - Focus on Overcoming Challenges in HER2 Status Interpretation;The Open Biomarkers Journal;2020-06-04

5. Loss of HER2 after HER2-targeted treatment;Breast Cancer Research and Treatment;2019-02-26